Takeda Provides Update on Voluntary Withdrawal Exkivity ® (mobocertinib)

OSAKA, Japan and CAMBRIDGE, Massachusetts, October 2, 2023– Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials